EP1232185A2 - Verfahren zur inhibierung von krebs-metastasen - Google Patents

Verfahren zur inhibierung von krebs-metastasen

Info

Publication number
EP1232185A2
EP1232185A2 EP00977216A EP00977216A EP1232185A2 EP 1232185 A2 EP1232185 A2 EP 1232185A2 EP 00977216 A EP00977216 A EP 00977216A EP 00977216 A EP00977216 A EP 00977216A EP 1232185 A2 EP1232185 A2 EP 1232185A2
Authority
EP
European Patent Office
Prior art keywords
receptor
chemokine
chemokine receptor
cell
antibody against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00977216A
Other languages
English (en)
French (fr)
Inventor
Anja Mueller
Albert Zlotnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Priority to EP10182021A priority Critical patent/EP2275447A1/de
Priority to EP10181315A priority patent/EP2261256A3/de
Publication of EP1232185A2 publication Critical patent/EP1232185A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00977216A 1999-11-24 2000-11-15 Verfahren zur inhibierung von krebs-metastasen Withdrawn EP1232185A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP10182021A EP2275447A1 (de) 1999-11-24 2000-11-15 Verfahren zur Inhibierung von Krebs Metastasen
EP10181315A EP2261256A3 (de) 1999-11-24 2000-11-15 Verfahren zur inhibierung von krebs metastasen

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US449060 1982-12-13
US44906099A 1999-11-24 1999-11-24
US22556200P 2000-08-14 2000-08-14
US225562P 2000-08-14
PCT/US2000/031230 WO2001038352A2 (en) 1999-11-24 2000-11-15 Methods of inhibiting metastasis

Publications (1)

Publication Number Publication Date
EP1232185A2 true EP1232185A2 (de) 2002-08-21

Family

ID=26919711

Family Applications (3)

Application Number Title Priority Date Filing Date
EP10181315A Withdrawn EP2261256A3 (de) 1999-11-24 2000-11-15 Verfahren zur inhibierung von krebs metastasen
EP10182021A Withdrawn EP2275447A1 (de) 1999-11-24 2000-11-15 Verfahren zur Inhibierung von Krebs Metastasen
EP00977216A Withdrawn EP1232185A2 (de) 1999-11-24 2000-11-15 Verfahren zur inhibierung von krebs-metastasen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP10181315A Withdrawn EP2261256A3 (de) 1999-11-24 2000-11-15 Verfahren zur inhibierung von krebs metastasen
EP10182021A Withdrawn EP2275447A1 (de) 1999-11-24 2000-11-15 Verfahren zur Inhibierung von Krebs Metastasen

Country Status (6)

Country Link
EP (3) EP2261256A3 (de)
JP (3) JP2003516324A (de)
AU (1) AU1488501A (de)
CA (1) CA2389979C (de)
MX (1) MXPA02005199A (de)
WO (1) WO2001038352A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US20030077247A1 (en) * 2001-09-20 2003-04-24 Schering Corporation Chemokines as adjuvants of immune response
AU2003261723A1 (en) 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
JP4781621B2 (ja) * 2002-08-27 2011-09-28 バイオカイン セラピューティックス リミテッド Ｃｘｃｒ４拮抗薬およびその用途
DE10240064A1 (de) * 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
CA2558813A1 (en) * 2004-03-09 2005-09-15 Kyoto University Pharmaceutical composition comprising cxcr3 inhibitor
JP2008535779A (ja) 2005-01-07 2008-09-04 エモリー・ユニバーシテイ Ｈｉｖ感染治療のためのｃｘｃｒ４拮抗薬
WO2008008854A2 (en) 2006-07-11 2008-01-17 Emory University Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders
EP3011961B1 (de) 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 für die mobilisierung von hämotopoietischen vorläuferzellen im hinblick auf transplantation
MX2010010619A (es) 2008-03-28 2010-12-17 Altiris Therapeutics Moduladores de quimioquina.
US7892546B2 (en) 2008-05-14 2011-02-22 Eli Lilly And Company Anti-CXCR4 antibodies
MX2011013459A (es) 2009-06-14 2012-05-08 Biokine Therapeutics Ltd Terapia de peptido para incrementar los niveles de plaquetas.
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
EP2841084B1 (de) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptid zur verwendung in der behandlung von lungenkrebs
EP3322431A2 (de) 2015-07-16 2018-05-23 Biokine Therapeutics Ltd. Zusammensetzungen und verfahren zur behandlung von krebs
AU2017222495B2 (en) 2016-02-23 2019-08-08 Biolinerx Ltd. Methods of treating acute myeloid leukemia
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
ATE290080T1 (de) 1994-08-23 2005-03-15 Human Genome Sciences Inc Menschliches beta-9 chemokin
US5605817A (en) * 1995-01-19 1997-02-25 Incyte Pharmaceuticals, Inc. DNA encoding chemokine expressed in fetal spleen
GB9617923D0 (en) * 1996-08-28 1996-10-09 Smithkline Beecham Plc Novel receptor
CA2265915C (en) * 1996-09-10 2012-11-20 Theodor-Kocher Institute Cxcr3 chemokine receptor, antibodies, nucleic acids, and methods of use
CA2274313A1 (en) * 1996-11-27 1998-06-04 Schering Corporation Mammalian chemokines
EP0897980A3 (de) * 1997-08-20 2002-04-17 Smithkline Beecham Corporation CXCR4B: Eine menschliche Spleissvariante des CXCR4 Chemokinrezeptors
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
ES2281205T3 (es) * 1998-12-24 2007-09-16 Schering Corporation Anticuerpos antagonistas de quimiocina de atraccion de celulas t cutaneas (ctack) o quimiocinas de contractor intestinal vasoactivo (vic).
EP1149113A1 (de) * 1999-02-03 2001-10-31 Schering Corporation Verwendung von agonisten oder antagonisten von mip-3a in der therapie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0138352A2 *

Also Published As

Publication number Publication date
WO2001038352A2 (en) 2001-05-31
CA2389979A1 (en) 2001-05-31
EP2261256A2 (de) 2010-12-15
JP2011132260A (ja) 2011-07-07
EP2275447A1 (de) 2011-01-19
JP2003516324A (ja) 2003-05-13
AU1488501A (en) 2001-06-04
MXPA02005199A (es) 2002-11-07
CA2389979C (en) 2011-08-16
EP2261256A3 (de) 2011-03-02
JP2014028860A (ja) 2014-02-13
WO2001038352A3 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
US7521045B2 (en) Methods of inhibiting metastasis
JP2014028860A (ja) 転移を阻害する方法
AU773293B2 (en) Anti-CCR4 antibodies and methods of use therefor
US7038018B2 (en) Antibodies and ligands for “Bonzo” chemokine receptor
JP4452839B2 (ja) Ｃｘｃｒ３阻害剤を含有する医薬組成物
US20020054875A1 (en) Therapeutic methods that target fractalkine or CX3CR1
JP2001518318A (ja) Ｌｅｒｋ−２媒介細胞接着の調節
CA2309761A1 (en) Th2 cell depletion; compositions; methods
US6645491B1 (en) Method for treating inflammatory conditions using an antibody to MIP-3α
WO2000046248A1 (en) Use of agonists or antagonists of mip-3a in therapy
US7208152B2 (en) Antibodies for “Bonzo” chemokine receptor and therapeutic uses thereof
US6207155B1 (en) Method of eosinophil depletion with antibody to CCR 3 receptor
US6416954B1 (en) Modulating Th2 cell levels via vMIP-I/CCR8 interaction
CA2288017A1 (en) Methods for eosinophil depletion and compositions therefor
MXPA01007938A (en) Use of agonists or antagonists of mip-3a in therapy
MXPA01007565A (en) Method of treating demyelinating inflammatory disease using ccr1 antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020522

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO PAYMENT 20020522;SI PAYMENT 20020522

17Q First examination report despatched

Effective date: 20040811

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK SHARP & DOHME CORP.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150601